May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Combined Intravitreal Gas Injection and Intravitreal Bevacizumab for Massive Submacular Hemorrhage Due to Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • M. Kitahashi
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • M. Kubota-Taniai
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • T. Baba
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • Y. Mitamura
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • S. Yamamoto
    Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan
  • Footnotes
    Commercial Relationships  M. Kitahashi, None; M. Kubota-Taniai, None; T. Baba, None; Y. Mitamura, None; S. Yamamoto, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5611. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Kitahashi, M. Kubota-Taniai, T. Baba, Y. Mitamura, S. Yamamoto; Combined Intravitreal Gas Injection and Intravitreal Bevacizumab for Massive Submacular Hemorrhage Due to Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5611. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the therapeutic efficacy of combined intravitreal bevacizumab and pneumatic displacement for a massive submacular hemorrhage due to polypoidal choroidal vasculopathy (PCV).

Methods: : A retrospective study on 5 patients with extensive and thick submacular hemorrhage secondary to PCV. The hemorrhage was displaced pneumatically with intravitreal 0.5 ml SF6, and 1.25 mg of bevacizumab was injected intravitreally. The evaluations included best-corrected visual acuity (BCVA) in logMAR units, optical coherence tomography (OCT)-determined foveal thickness (FT), and fluorescein and indocyanine green angiography before and 3 month after the treatment.

Results: : The submacular hemorrhages were displaced inferiorly in all patients. The mean BCVA was improved significantly from 1.21±0.68 to 0.97±0.70(P=0.043).The mean FT decreased significantly from 572±134 µm to 294±194 µm (P=0.043). Leakages from the PCV were resolved in all cases.

Conclusions: : Combined therapy with intravitreal gas injection and intravitreal bevacizumab for massive submacular hemorrhage secondary to PCV is relatively successful and well-tolerated. Further comparative studies with larger sample size and longer follow-up are warranted.

Keywords: choroid: neovascularization • macula/fovea • vitreoretinal surgery 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×